A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

cUHDRS includes the Total Functional Capacity (range, 0-13; higher score means better functioning), Total Motor Score (range, 0-124; higher score means worse motor severity), Symbol Digit Modality Test (range, 0-110, correctly paired numbers-symbols in 90 seconds; higher score means better cognitive performance), and Stroop Word Reading (range, 0-no max value, correctly read colour words in 45 seconds; higher score means better cognitive performance) scores. A z-score for each test is calculated, which alone can be used to describe relationship between an individual's test score and the mean score of a target population. A z-score of 0 is the mean, and ±1 is 1 standard deviation from the mean. For cUHDRS, z-scores of each test are summed, whereby a higher cUHDRS score is better (score of -3.06-no max value) and a change of ≥1.2 is a meaningful worsening, shown to track functional decline.

Time frame: Weeks 21 for ODC and 69 for NDC

Population: ITT Population. Only those participants who contributed to data reported in the table. All other data were not evaluable.

Total Functional Capacity (TFC) Scores are reported at Weeks 21 and 69. Total Functional Capacity Score ranges from 0 to 13, with a higher score representing better functioning.

Time frame: Weeks 21 for ODC and 69 for NDC

Population: ITT Population. Only those participants who contributed to data reported in the table. All other data were not evaluable.

Data to be reported within 12 months after the primary completion.

Time frame: Baseline, Week 101

Time frame: Week 21 for ODC, Weeks 21 and 69 for NDC

Population: ITT Population. Only those participants who were contributed data reported in the table. All other data were not evaluable. No data could be reported in ODC Arm Week 69 due to no data were collected.

ODC Week 21 and NDC Week 69 data were reportable. Total MOCA scores are reported. The MoCA is a patient-completed assessment used to detect cognitive impairment. It contains a series of basic assessments, including attention and visuospatial tasks. The total score ranges from 0-30, where lower scores indicate greater impairment.

Time frame: Up to Week 21 for ODC, Up to Week 69 for NDC

Population: ITT Population. Only those participants who were contributed data reported in the table. All other data were not evaluable.~NDC participants number are different at Week 21 and 69, reported data are from all evaluable participants.

Stroop Word Reading-SWR number of words and colors read correctly is counted, with a higher score indicating better cognitive performance scores. There is no upper limit for SWR as it is a time based task. The lower limit (worst possible) however is 0; higher score is better meaning less severity. The differences in LS mean ( +/-SE) change from baseline SWR score between the active groups compared with the placebo group at Weeks 21 and 69 were reported. A negative change from baseline in the SWR indicates disease progression. The Least Square Mean values of Stroop Word Reading (SWR) Test Scores are reported below.

Time frame: Weeks 21 for ODC and 69 for NDC

Population: ITT Population. Only those participants who contributed to data reported in the table. All other data were not evaluable.

Symbol Digit Modality Test -SDMT test measures the number of items correctly paired maximum of 110 correct pairs in 90 seconds, more correctly paired items representing less impairment. The differences in LS mean ( +/-SE) change from baseline SDMT score between the active groups compared with the placebo group at Weeks 21 and 69 were reported. A negative change from baseline in the SDMT indicates disease progression. The Least Square Mean values of Symbol Digit Modality Test Scores are reported below. The minimum range for the SDMT scale is 0, indicating highest severity. A max number is not possible as it is a time based task, based on the number of correct answers within a set time frame. There are no validated SDMT score thresholds to indicate the level of HD symptom severity.

Time frame: Weeks 21 for ODC and 69 NDC

Population: ITT Population. Only those participants who contributed to data reported in the table. All other data were not evaluable.

The CGI-S is a single-item measure of current global severity and is completed by the clinician at specified clinic visits. The CGI-S is assessed using an 11-point numeric rating scale (NRS), where higher scores indicate greater severity. Only NDC participants data were reported, all other data were not available. CGI-S) Scores range from 0 (not at all severe) to 10 (Extremely severe); lower score is better meaning less severity.

Time frame: Week 69 for NDC Only

Population: ITT Population. Only those participants who were contributed data reported in the table. All other data were not evaluable. No data could be reported in ODC Arms due to no data were collected.

The TMS score is the sum of the individual motor ratings obtained from administration of the 31-item motor assessment. The score ranges from 0 to 124, with a higher score representing more severe impairment.

Time frame: Weeks 21 for ODC and 69 for NDC

Population: ITT Population. Only those participants who contributed to data reported in the table. All other data were not evaluable.

Data reported only for ODC Arms. Analysis of Percent Change from Baseline in Volumetric MRI / BSI at 3 Months reported. Analysis performed using analysis of covariance with covariates of CAP, CAG, Age at Baseline and treatment included. Analysis of Change from Baseline in: Caudate Volume (mL)

Time frame: Week 13 for ODC

Population: Pharmacokinetic Population. Only those participants who were contributed data reported in the table. All other data were not evaluable. No data could be reported in NDC Arm Week due to no data were collected, no participants were involved in this Arm.

Concentration of tominersen in plasma reported

Time frame: Week 21 for ODC and Week 69 for NDC

Population: Pharmacokinetic Population. Only those participants who were contributed data reported in the table. All other data were not evaluable.~NDC participants number are different at Week 21 and 69, reported data are from all evaluable participants.

Data at Weeks 21 and 69 for Old Design and New Design Cohorts are reported respectively. All other timepoints were not evaluable and not meaningful.

Time frame: Week 21 for ODC and Week 69 for NDC

Population: Pharmacokinetic Population. Only those participants who were contributed data reported in the table. All other data were not evaluable.

Time frame: Up to 117 Weeks (29 months)

Population: Safety Population

SI-Suicidal Idealation. For ODC, only Treatment Emergent Suicide-Related Events Based on the Columbia-Suicide Severity Rating Scale (CSSRS) are reported. Four constructs are measured: severity of ideation, intensity of ideation, behavior, and lethality of actual suicide attempts. Binary (yes/no) data are collected for 10 categories, and composite endpoints based on the categories are followed over time to monitor patient safety (Posner et al. 2011). It maps to the Columbia-Classification Algorithm for Suicide Assessment and meets the criteria listed in the U.S. FDA draft guidance for assessment of suicidality in clinical trials (FDA 2012). The higher scores indicate higher severity

Time frame: For ODC at 13th Month, for NDC at Week 101

Population: Safety Population

Only NDC participant data are available and reported. The cUHDRS is comprised of the sum scores of the subscales, score ranges and severities mentioned in the Outcome Measure Description 1 (please see above). In this outcome measure, participants with 1.2 or higher point score decrease from the Baseline Composite Unified Huntington's Disease Rating Scale- cUHDRS Total Score was considered. The Percentage of these participants with such a change was calculated. cUHDRS lowest (worst) score possible value is -3.06 but no upper limit as it involves SWR; higher score is better meaning less severity.

Time frame: Week 69 for NDC Only

Population: ITT Population. Only those participants who were contributed data reported in the table. All other data were not evaluable. No data could be reported in ODC Arms due to no data were collected.

Only NDC participant data are available and reported. Total Functional Capacity-TFC score ranges from 0 to 13, with a higher score representing better functioning. In this outcome measure, participants with 1 or higher point score decrease from the Baseline TFC Total Score was considered. The Percentage of these participants with such a change was calculated.

Time frame: Week 69 for NDC only

Population: ITT Population. Only those participants who contributed to data reported in the table. All other data were not evaluable. No data could be reported in ODC Arms due to no data were collected.

The Clinical Global Impression, Change - CGI-C Scale is a single-item measure of change in global status scale and total scores are summed and reported. The CGI-C has 7 response options: very much worse, much worse, minimally worse, no change, minimally improved, much improved, and very much improved. Yes, No responses collected and total scores are summed and reported below. Percentage of participants who have unchanged or improved scores from the Baseline CGI-C Scores are calculated and reported here. Total CGI-C scores range from 1 (Very much improved) to 7 (Very much worse); lower score is better meaning less severity. Only NDC Arms data were available. Minimum and maximum values are 1 and 7 respectively.

Time frame: Weeks 53 and 69 NDC only

Population: ITT Population. Only those participants who were contributed data reported in the table. All other data were not evaluable. No data could be reported in ODC Arms due to no data were collected.

Titer and Antibody Subtype was not analyzed and there is not data to report due to participants' discontinuation

Time frame: Week 21 for ODC and Week 69 for NDC

Population: No participants and no data to report

Tominersen concentrations in cerebrospinal fluid

Time frame: Week 21 for ODC and Week 69 for NDC

Population: Pharmacokinetic Population. Only those participants who were contributed data reported in the table. All other data were not evaluable.~NDC participants number are different at Week 21 and 69, reported data are from all evaluable participants.